FDA Seeks More Data Before OK’ing Extended Use Of Brain Electrodes
The U.S. Food and Drug Administration (FDA) has upheld its decision that the Evo stereoelectroencephalography (sEEG) electrode, designed to monitor brain activity in people with Parkinson’s disease and other neurological conditions in a minimally invasive way, cannot be marketed for long-term use until more safety data is provided. Last…